'Columbia University Libraries/Information Services'
Doi
Abstract
This is an author response to the letter by doctors Nicholas Doher and Harsh V Gupta. Despite the narrow indication for the dopamine transporter (DAT) scan to distinguish essential tremor from Parkinsonian syndromes, as approved by the Food and Drug Administration (FDA), DAT imaging is utilised for various other clinical symptoms in patients with parkinsonism. DAT scan is the only non-invasive modality developed to assess functional integrity of the dopaminergic system currently used in clinical practice, and could give valuable clinical information for selected patients. The authors believe that the approved indication of the DAT scan will be broadened to meet its versatile diagnostic potential
